The diagnosis and treatment of autoimmune blistering skin diseases;Diagnostik und therapie bullöser autoimmundermatosen

Deutsches Arzteblatt

Volumn 108, Issue 23, 2011, Pages 399-405

  Schmidt, Enno ^a   Zillikens, Detlef ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; AUTOANTIBODY; IMMUNOGLOBULIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; RITUXIMAB; STRUCTURAL PROTEIN;

AUTOIMMUNE BLISTERING SKIN DISEASE; AUTOIMMUNE SKIN DISEASE; CLINICAL FEATURE; DENTIST; DERMATITIS HERPETIFORMIS; DERMATOLOGY; DESMOSOME; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DRUG MEGADOSE; EPIDERMIS; EPIDERMOLYSIS BULLOSA ACQUISITA; GENERAL PRACTITIONER; GERMANY; GYNECOLOGY; HEMIDESMOSOME; HUMAN; IMMUNOADSORPTION; OPHTHALMOLOGY; PEDIATRICIAN; PEMPHIGUS; PRACTICE GUIDELINE; REVIEW; SENSITIVITY AND SPECIFICITY;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; CROSS-SECTIONAL STUDIES; EUROPE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOLOGIC FACTORS; IMMUNOSORBENT TECHNIQUES; SKIN DISEASES, VESICULOBULLOUS;

EID: 79960645533     PISSN: 00121207     EISSN: 01722107     Source Type: Journal    
DOI: 10.3238/arztebl.2011.0399     Document Type: Review

References (100)

1. Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J: Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: population based cohort study. BMJ 2008; 337: a180.
2. Schmidt E, Dähnrich C, Rosemann A, et al.: Novel ELISA systems for antibodies to desmoglein 1 and 3: Correlation of disease activity with serum autoantibody levels in individual pemphigus patients. 2010; 19: 458-63.
3. Egan CA, Lazarova Z, Darling TN, Yee C, Cote T, Yancey KB: Antiepiligrin cicatricial pemphigoid and relative risk for cancer. Lancet 2001; 357: 1850-1. (Pubitemid 32539120)
4. Zillikens D, Kawahara Y, Ishiko A, et al.: A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone. J Invest Dermatol 1996; 106: 1333-8. (Pubitemid 26194248)
5. Dainichi T, Kurono S, Ohyama B, et al.: Anti-laminin gamma-1 pemphigoid. Proc Natl Acad Sci U S A 2009; 106: 2800-5.
6. Woodley DT, Briggaman RA, O'Keefe EJ, Inman AO, Queen LL, Gammon WR: Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med 1984; 310: 1007-13. (Pubitemid 14129233)
7. Sardy M, Karpati S, Merkl B, Paulsson M, Smyth N: Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med 2002; 195: 747-57. (Pubitemid 34259719)
8. Schmidt E, Obe K, Brocker EB, Zillikens D: Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000; 136: 174-8. (Pubitemid 30090755)
9. Khumalo N, Kirtschig G, Middleton P, Hollis S, Wojnarowska F, Murrell D: Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2005; CD002292.
10. Martin LK, Werth V, Villanueva E, Segall J, Murrell DF: Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev 2009; CD006263.
11. Harman KE, Albert S, Black MM: Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003; 149: 926-37. (Pubitemid 37541976)
12. Wojnarowska F, Kirtschig G, Highet AS, Venning VA, Khumalo NP: Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002; 147: 214-21.
13. Chan LS, Ahmed AR, Anhalt GJ, et al.: The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138: 370-9. (Pubitemid 34226335)
14. Joly P, Roujeau JC, Benichou J, et al.: A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346: 321-7. (Pubitemid 34438839)
15. Beissert S, Werfel T, Frieling U, et al.: A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 2006; 142: 1447-54. (Pubitemid 44790638)
16. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al.: Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007; 57: 622-8. (Pubitemid 47384928)
17. Amagai M, Ikeda S, Shimizu H, et al.: A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009; 60: 595-603.
18. Enk A, Fierlbeck G, French L, et al.: Use of high-dose immunoglobulins in dermatology. J Dtsch Dermatol Ges 2009; 7: 806-12.
19. Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA: Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982; 306: 1189-96. (Pubitemid 12158848)
20. Sitaru C, Mihai S, Otto C, et al.: Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest 2005; 115: 870-8. (Pubitemid 40489391)
21. Schmidt E, Klinker E, Opitz A, et al.: Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 2003; 148: 1222-9. (Pubitemid 36819223)
22. Zillikens D, Derfler K, Eming R, et al.: Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. J Dtsch Dermatol Ges 2007; 5: 881-7.
23. Nagel A, Hertl M, Eming R: B-cell-directed therapy for inflammatory skin diseases. J Invest Dermatol 2009; 129: 289-301.
24. Schmidt E, Seitz CS, Benoit S, Brocker EB, Goebeler M: Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007; 156: 352-6. (Pubitemid 46095965)
25. Hertl M, Zillikens D, Borradori L, et al.: Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008; 6: 366-73.
26. Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T: The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 1999; 40: 167-70.
27. Anhalt GJ, Kim SC, Stanley JR, et al.: Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323: 1729-35.
28. Anhalt GJ: Paraneoplastic pemphigus. J Investig Dermatol Symp Proc 2004; 9: 29-33.
29. Zimmermann J, Bahmer F, Rose C, Zillikens D, Schmidt E: Clinical and immunopathological spectrum of paraneoplastic pemphigus. J Dtsch Dermatol Ges 2010; 8: 598-605.
30. Kippes W, Schmidt E, Roth A, Rzany B, Brocker EB, Zillikens D: Immunopathologic changes in 115 patients with bullous pemphigoid. Hautarzt 1999; 50: 866-72.
31. Hahn-Ristic K, Rzany B, Amagai M, Brocker EB, Zillikens D: Increased incidence of pemphigus vulgaris in southern Europeans living in Germany compared with native Germans. J Eur Acad Dermatol Venereol 2002; 16: 68-71.
32. Bernard P, Vaillant L, Labeille B, et al.: Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol 1995; 131: 48-52.
33. Zillikens D, Wever S, Roth A, Weidenthaler-Barth B, Hashimoto T, Brocker EB: Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. Arch Dermatol 1995; 131: 957-8.
34. Bertram F, Brocker EB, Zillikens D, Schmidt E: Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 2009; 7: 434-40.
35. Marazza G, Pham HC, Scharer L, et al.: Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 2009; 161: 861-8.
36. Jung M, Kippes W, Messer G, Zillikens D, Rzany B: Increased risk of bullous pemphigoid in male and very old patients: A population-based study on incidence. J Am Acad Dermatol 1999; 41: 266-8.
37. Beutner EH, Jordon RE: Demonstration of skin antibodies in sera of pemphigus vulgaris patients by indirect immunofluorescent staining. Proc Soc Exp Biol Med 1964; 117: 505-10.
38. Kelly SE, Wojnarowska F: The use of chemically split tissue in the detection of circulating anti-basement membrane zone antibodies in bullous pemphigoid and cicatricial pemphigoid. Br J Dermatol 1988; 118: 31-40.
39. Schmidt E, Zillikens D: Research in practice: diagnosis of subepidermal autoimmune bullous disorders. J Dtsch Dermatol Ges 2009; 7: 296-300.
40. Amagai M, Komai A, Hashimoto T, et al.: Usefulness of enzymelinked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol 1999; 140: 351-7.
41. Ishii K, Amagai M, Hall RP, et al.: Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997; 159: 2010-7.
42. Nagata Y, Karashima T, Watt FM, Salmhofer W, Kanzaki T, Hashimoto T: Paraneoplastic pemphigus sera react strongly with multiple epitopes on the various regions of envoplakin and periplakin, except for the c-terminal homologous domain of periplakin. J Invest Dermatol 2001; 116: 556-63.
43. Zhang B, Zheng R, Wang J, Bu D, Zhu X: Epitopes in the linker subdomain region of envoplakin recognized by autoantibodies in paraneoplastic pemphigus patients. J Invest Dermatol 2006; 126: 832-40.
44. Probst C, Schlumberger W, Stocker W, et al.: Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus. Clin Chim Acta 2009; 410: 13-8.
45. Zillikens D, Mascaro JM, Rose PA, et al.: A highly sensitive enzyme- linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol 1997; 109: 679-83.
46. Sitaru C, Dahnrich C, Probst C, et al.: Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Exp Dermatol 2007; 16: 770-7.
47. Kromminga A, Scheckenbach C, Georgi M, et al.: Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180. J Autoimmun 2000; 15: 293-300.
48. Mulyowa GK, Jaeger G, Kabakyenga J, Brocker EB, Zillikens D, Schmidt E: Autoimmune subepidermal blistering diseases in Uganda: correlation of autoantibody class with age of patients. Int J Dermatol 2006; 45: 1047-52.
49. Iwata Y, Komura K, Kodera M, et al.: Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol 2008; 144: 41-8.
50. Dopp R, Schmidt E, Chimanovitch I, Leverkus M, Brocker EB, Zillikens D: IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol 2000; 42: 577-83.
51. Kromminga A, Sitaru C, Hagel C, Herzog S, Zillikens D: Development of an ELISA for the detection of autoantibodies to BP230. Clin Immunol 2004; 111: 146-52.
52. Schmidt E, Kromminga A, Mimietz S, et al.: A highly sensitive and simple assay for the detection of circulating autoantibodies against full-length bullous pemphigoid antigen 180. J Autoimmun 2002; 18: 299-309.
53. Yoshida M, Hamada T, Amagai M, et al.: Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid. J Dermatol Sci 2006; 41: 21-30.
54. Chan LS: Epitope spreading in paraneoplastic pemphigus: autoimmune induction in antibody-mediated blistering skin diseases. Arch Dermatol 2000; 136: 663-4.
55. Sitaru C, Powell J, Messer G, Brocker EB, Wojnarowska F, Zillikens D: Immunoblotting and enzyme-linked immunosorbent assay for the diagnosis of pemphigoid gestationis. Obstet Gynecol 2004; 103: 757-63.
56. Di Zenzo G, Calabresi V, Grosso F, Caproni M, Ruffelli M, Zambruno G: The intracellular and extracellular domains of BP180 antigen comprise novel epitopes targeted by pemphigoid gestationis autoantibodies. J Invest Dermatol 2007; 127: 864-73.
57. Tamada Y, Yokochi K, Nitta Y, Ikeya T, Hara K, Owaribe K: Lichen planus pemphigoides: identification of 180 kd hemidesmosome antigen. J Am Acad Dermatol 1995; 32: 883-7.
58. Zillikens D, Caux F, Mascaro JM, et al.: Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180. J Invest Dermatol 1999; 113: 117-21.
59. Marinkovich MP, Taylor TB, Keene DR, Burgeson RE, Zone JJ: LAD-1, the linear IgA bullous dermatosis autoantigen, is a novel 120-kDa anchoring filament protein synthesized by epidermal cells. J Invest Dermatol 1996; 106: 734-8.
60. Zillikens D, Herzele K, Georgi M, et al.: Autoantibodies in a subgroup of patients with linear IgA disease react with the NC16A domain of BP1801. J Invest Dermatol 1999; 113: 947-53.
61. Schmidt E, Skrobek C, Kromminga A, et al.: Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intraand extracellular domains of bullous pemphigoid antigen 180. Br J Dermatol 2001; 145: 778-83.
62. Oyama N, Setterfield JF, Powell AM, et al.: Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity. Br J Dermatol 2006; 154: 90-8.
63. Bedane C, McMillan JR, Balding SD, et al.: Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida. J Invest Dermatol 1997; 108: 901-7.
64. Lazarova Z, Hsu R, Yee C, Yancey KB: Antiepiligrin cicatricial pemphigoid represents an autoimmune response to subunits present in laminin 5 (alpha3beta3gamma2). Br J Dermatol 1998; 139: 791-7.
65. Leverkus M, Schmidt E, Lazarova Z, Brocker EB, Yancey KB, Zillikens D: Antiepiligrin cicatricial pemphigoid: an underdiagnosed entity within the spectrum of scarring autoimmune subepidermal bullous diseases? Arch Dermatol 1999; 135: 1091-8.
66. Lapiere JC, Woodley DT, Parente MG, et al.: Epitope mapping of type VII collagen. Identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa. J Clin Invest 1993; 92: 1831-9.
67. Rose C, Armbruster FP, Ruppert J, Igl BW, Zillikens D, Shimanovich I: Autoantibodies against epidermal transglutami - nase are a sensitive diagnostic marker in patients with dermatitis herpetiformis on a normal or gluten-free diet. J Am Acad Dermatol 2009; 61: 39-43.
68. Harman KE, Seed PT, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM: The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol 2001; 144: 775-80.
69. e44. Hofmann SC, Kautz O, Hertl M, Sticherling M, Zillikens D, Bruckner-Tuderman L: Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid. J Dtsch Dermatol Ges 2009; 7: 227-33.
70. Goebeler M, Sitaru C, Zillikens D: Blistering autoimmune dermatoses (II): therapy. J Dtsch Dermatol Ges 2004; 2: 774-91.
71. Mutasim DF: Management of autoimmune bullous diseases: pharmacology and therapeutics. J Am Acad Dermatol 2004; 51: 859-77; quiz 878-80.
72. Bystryn JC, Rudolph JL: Pemphigus. Lancet 2005; 366: 61-73.
73. Kasperkiewicz M, Schmidt E: Current treatment of autoimmune blistering diseases. Curr Drug Discov Technol 2009; 6: 270-80.
74. Rosenberg FR, Sanders S, Nelson CT: Pemphigus: a 20-year review of 107 patients treated with corticosteroids. Arch Dermatol 1976; 112: 962-70.
75. Benoit S, Bröcker EB, Schmidt E: Current treatment of pemphigus. G Ital Dermatol Venereol 2007; 142: 363-80.
76. Kirtschig G, Murrell D, Wojnarowska F, Khumalo N: Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. Arch Dermatol 2002; 138: 380-4.
77. Joly P, Roujeau JC, Benichou J, et al.: A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol 2009; 129: 1681-7.
78. El-Darouti M, Marzouk S, Abdel Hay R, et al.: The use of sulfasalazine and pentoxifylline (low-cost antitumour necrosis factor drugs) as adjuvant therapy for the treatment of pemphigus vulgaris: a comparative study. Br J Dermatol 2009; 161: 313-9.
79. Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ: Treating pemphigus vulgaris with prednisone and mycophenolate Mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol 2010; 130: 2041-8.
80. Cooper SM, Powell J, Wojnarowska F: Linear IgA disease: successful treatment with erythromycin. Clin Exp Dermatol 2002; 27: 677-9.
81. Schmidt E, Meyer-Ter-Vehn T, Zillikens D, Geerling G: Mucous membrane pemphigoid with ocular involvement. Part I: Clinical manifestations, pathogenesis and diagnosis. Ophthalmologe 2008; 105: 285-97.
82. Meyer-ter-Vehn T, Schmidt E, Zillikens D, Geerling G: Mucous membrane pemphigoid with ocular involvement. Part II: therapy. Ophthalmologe 2008; 105: 405-19.
83. Saw VP, Dart JK, Rauz S, et al.: Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology 2008; 115: 253-261.
84. Foster CS: Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986; 84: 527-663.
85. Ishii N, Hashimoto K, Zillikens D, Ludwig RJ: High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases. Clin Rev Allergy Immunol 2010; 38: 186-95.
86. Engineer L, Bhol KC, Ahmed AR: Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris. J Am Acad Dermatol 2000; 43: 1049-57.
87. Ahmed AR: Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001; 45: 679-90.
88. Herzog S, Schmidt E, Goebeler M, Brocker EB, Zillikens D: Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins. Acta Derm Venereol 2004; 84: 48-52.
89. Czernik A, Bystryn JC: Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodies. Arch Dermatol 2008; 144: 658-61.
90. Katz U, Achiron A, Sherer Y, Shoenfeld Y: Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007; 6: 257-9.
91. Amagai M, Hashimoto T, Shimizu N, Nishikawa T: Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994; 94: 59-67.
92. Liu Z, Diaz LA, Troy JL, et al.: A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993; 92: 2480-8.
93. Sitaru C, Chiriac MT, Mihai S, et al.: Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice. J Immunol 2006; 177: 3461-8.
94. Shimanovich I, Herzog S, Schmidt E, et al.: Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin Exp Dermatol 2006; 31: 768-74.
95. Lüftl M, Stauber A, Mainka A, Klingel R, Schuler G, Hertl M: Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol 2003; 149: 598-605.
96. Schmidt E, Zillikens D: Immunoadsorption in dermatology. Arch Dermatol Res 2010; 302: 241-53.
97. Eming R, Rech J, Barth S, et al.: Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology 2006; 212: 177-87.
98. Schmidt E, Goebeler M: CD20-directed therapy in autoimmune diseases involving the skin: role of rituximab. Expert Rev Dermatol 2008; 3: 259-278.
99. Schmidt E, Goebeler M, Zillikens D: Rituximab in severe pemphigus. Ann N Y Acad Sci 2009; 1173: 683-91.
100. Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D: Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 2008; 158: 382-8.